Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced the presentations of new biomarker and subgroup analyses from the Phase 3 NefIgArd study with Nefecon (TARPEYO[®] (budesonide) delayed release capsules/Kinpeygo[®]) in adults with Primary IgA nephropathy (IgAN). The data was presented in both posters and oral presentations at the 17th International Symposium on IgA Nephropathy (IIGaNN), held in Tokyo, Japan, on September 25-27, 2023.“We are proud to have showcased new data at this year’s International Symposium on IgAN in Tokyo,” said Richard